Webinars & Videos
Featured
Learn what the Fragile X premutation is in just 90 seconds. This short animated video from the National Fragile X Foundation explains how the Fragile X premutation affects individuals and families—and why awareness matters.
Latest
Chad Coberly, CEO of Tetra Therapeutics, a Shionogi Group Company, presented about BPN14770, a PDE4 inhibitor, during the Industry Updates keynote session at the 18th International Fragile X Conference.
Kelly Piacenti shared insights and resources to help families understand how a letter of intent can be vital in creating a comprehensive care plan.
All Webinars and Videos
Kelly Piacenti shared insights and resources to help families understand how a letter of intent can be vital in creating a comprehensive care plan.
Dres. Wilmar Saldarriaga Gil y Ana María Cabal se unen a Johana LaTorre, Judith García, Nelsy Garzón, María Vera, Carolina Rabazani y Facundo Mattea para discutir la genética y las características clínicas del síndrome de X frágil.
La Dra. Bibiana Restrepo, un pediatra del desarrollo conductual certificado por la junta de la Universidad de California y el Instituto MIND, se reúne con Johana Latorre, Lorena Reisenauer, Luz Elena Paez y Paula Bahlcke en una discusión sobre las características conductuales en el SXF.
Una discusión sobre los medicamentos para el síndrome del cromosoma X frágil, con la Dra. Randi J. Hagerman, profesora distinguida de Pediatría, presidenta de investigación del síndrome del cromosoma X frágil e investigadora del Instituto MIND de UC Davis.
Learn what the Fragile X premutation is in just 90 seconds. This short animated video from the National Fragile X Foundation explains how the Fragile X premutation affects individuals and families—and why awareness matters.
These conference sessions explore key findings from the CDC-funded study, FORWARD, covering adult life, medical and sensory challenges, behavioral subtypes, and aging in individuals with Fragile X syndrome. This expert-led series offers valuable insights to support clinical care, research, and long-term planning for individuals with FXS across the lifespan.
These conference sessions explore the latest Fragile X syndrome research on maternal labeling and vocabulary, coping and well-being in FXS mothers, FMRP’s link to IQ, behavioral-cognitive subtypes, and innovative brain rhythm therapies using AI-driven sound stimulation to boost learning in children with FXS.
Join Dr. Peter Todd as he shares the collective hope and anticipation surrounding the promising future of treatments for Fragile X-associated conditions. In this keynote session at the 19th NFXF International Fragile X Conference, Dr. Todd discusses the history, challenges, and advancements that have helped shape the trajectory of treatments for Fragile X-associated conditions.
These conference sessions explore cutting-edge Fragile X premutation research uncovering how RAN translation and CGG repeat RNA toxicity drive FXTAS neurodegeneration, and how the epigenetic regulator Tet2 influences ovarian dysfunction in premutation carriers — highlighting new mechanisms and therapeutic targets.
These conference sessions explore new insights into Fragile X premutation carriers, including cognitive profiles in school-age children, healthcare experiences of women with FXPOI, one-year progression of FXTAS, and tremor characteristics in FXTAS vs. non-FXTAS premutation carriers.